Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Lengthy essay in NYT: Revolution in Cancer Treatment

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 18, 2023 4:11pm

121 Views

Post# 35502614

RE:RE:RE:RE:Lengthy essay in NYT: Revolution in Cancer Treatment

And then maybe the NYT reads what others say such as David Wainer of the Wall Street Journal (WSJ) who recenty wrote that it's a "seller's market in biotech," thanks in part to the "diminishing list of desirable biotechs" and the fact that other pharma companies are in Pfizer's shoes: "About $200 billion in sales is going off patent this decade." he said.

<< Previous

Bullboard Posts

Next >>

StockTalk | Cannabis Report: New CEO, new dispensaries, new strains